WP
HUMA icon

Woodline Partners’s Humacyte HUMA Stock Holding History

Woodline Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
2,002,582
+509
+0% +$529 ﹤0.01% 859
2025
Q4 		$1.92M Hold
2,002,073
– – 0.01% 772
2025
Q3 		$3.48M Buy
2,002,073
+680
+0% +$1.33K 0.02% 639
2025
Q2 		$4.18M Sell
2,001,393
-1,948,607
-49% -$3.74M 0.02% 598
2025
Q1 		$6.73M Buy
3,950,000
+1,101,198
+39% +$4.13M 0.04% 433
2024
Q4 		$14.4M Buy
2,848,802
+2,000,268
+236% +$9.9M 0.1% 273
2024
Q3 		$4.62M Buy
+848,534
New +$5.59M 0.04% 395

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Woodline Partners's HUMA Position: Q1 2026 in Review

Woodline Partners increased its Humacyte (HUMA) stake by 0.03% in Q1 2026, buying an estimated $529 and bringing the position to 2,002,582 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #859.

Woodline Partners first reported a position in HUMA in Q3 2024 and has held it in 7 quarters since. The position peaked at $14.4M in Q4 2024. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Woodline Partners held 2,002,582 shares of Humacyte worth $1.21M as of Q1 2026.
  • Woodline Partners bought 509 Humacyte shares in Q1 2026, an estimated $529.
  • Humacyte made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #859 holding.
  • Woodline Partners first reported a position in Humacyte in Q3 2024 and has held it in 7 quarters since.
  • Woodline Partners's Humacyte position peaked at $14.4M in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.